Первая клетка. И чего стоит борьба с раком до последнего

Fuchs Ota, ed. Recent Developments in Myelodysplastic Syndromes. London: IntechOpen, 2019.

Platzbecker U. Treatment of MDS. Blood. 133, no. 10 (2019): 1096–1107.

Ferrara F., Vitagliano O. Induction Therapy in Acute Myeloid Leukemia: Is It Time to Put Aside Standard 3 + 7? Hematological Oncology. (2019). doi:10.1002/hon.2615.

Cerrano M., Itzykson R. New Treatment Options for Acute Myeloid Leukemia in 2019. Current Oncology Reports. 21, no. 2 (2019): 16.

Buccisano F. The Emerging Role of Measurable Residual Disease Detection in AML in Morphologic Remission. Seminars in Hematology. 56, no. 2 (2019): 125–130.

Almeida A. et al. Recent Advances in the Treatment of Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS). Leukemia Research. 52 (2017): 50–57.

Luspatercept – Acceleron Pharma/Celgene Corporation. Adis Insight.

https://adisinsight.springer.com/drugs/800029519

Fenaux P. Luspatercept for the Treatment of Anemia in Myelodysplastic Syndromes and Primary Myelofibrosis. Blood. 133, no. 8 (2019): 790–794.

Prasad V. Do Cancer Drugs Improve Survival or Quality of Life? BMJ. 359 (2017): j4528.

Prasad V. et al. The High Price of Anticancer Drugs: Origins, Implications, Barriers, Solutions. Nature Reviews Clinical Oncology. 14 (2017): 381–390.

Keshavan M. Did He Really Just Tweet That? Dr. Vinay Prasad Takes on Big Pharma, Big Medicine, and His Own Colleagues – With Glee. Stat, September 15, 2017.

Exceptional Responders: Why Do Some Cancer Drugs Work for Them and Not Others? Cancer Treatment Centers of America, March 8, 2018. www.cancercenter.com/community/blog/2018/03/why-do-some-cancer-drugs-work-for-them-and-not-others

Milowsky M. I. et al. Phase II Study of Everolimus in Metastatic Urothelial Cancer. BJU International. 112, no. 4 (2013): 462–470.

NCI Sponsored Trials in Precision Medicine. Division of Cancer Treatment and Diagnosis. https://dctd.cancer.gov/majorinitiatives/NCI-sponsored_trials_in_precision_medicine.htm

West H. Novel Precision Medicine Trial Designs Umbrellas and Baskets. JAMA Oncology. 3, no. 3 (2017): 423.

Marquart J. et al. Estimation of the Percentage of US Patients with Cancer Who Benefit from Genome-Driven Oncology. JAMA Oncology. 4, no. 8 (2018): 1093–1098.

Prasad V. Perspective: The Precision-Oncology Illusion. Nature. 537 (2016): S63.

Kaiser J. A Cancer Drug Tailored to Your Tumor? Experts Trade Barbs over “Precision Oncology”. Science, April 24, 2018. doi:10.1126/science.aat9794.

Harris L. et al. Update on the NCI—Molecular Analysis for Therapy Choice (NCI—MATCH/EAY131) Precision Medicine Trial. Pharmacogenetics, Pharmacogenomics, and Therapeutic Response. 17, supplement 1 (2018). doi:10.1158/1535–7163. TARG-17-B080.

Davis C. et al. Availability of Evidence of Benefits on Overall Survival and Quality of Life of Cancer Drugs Approved by European Medicines Agency: Retrospective Cohort Study of Drug Approvals, 2009–13. BMJ. 359 (2017). doi:10.1136/bmj.j4530.

Drilon A. et al. Efficacy of Larotrectinib in TRK Fusion – Positive Cancers in Adults and Children. New England Journal of Medicine. 378 (2018): 731–739.